COVID-19: Vaccines and Therapeutics
Johnson & Johnson announced it accelerated the initiation of its first human trials of its coronavirus vaccine candidate, with the trial slated to begin in the second half of July.
Please join us this Friday, May 29, at 1 pm ET for the 6th installment of the “Securing the Health Sector” webinar series, hosted jointly by InfraGard National Capital Region (InfraGardNCR), the U.S
Criminal and nation-state cyber actors since February 2020 have been increasingly targeting US pharmaceutical, medical, and biological research facilities to acquire or manipulate sensitive information, to include COVID-19 vaccine and treatment research amid the evolving global pandemic.
A collaboration between the Department of Health and Human Services and AstraZeneca is projected to make available 300 million doses of a COVID-19 vaccine, the first of which could be available as early as October, HHS said.
The Trump administration introduced Operation Warp Speed, a $10 billion public-private partnership intended to accelerate development, manufacturing and distribution of COVID-19 vaccines, therapeutics and diagnostics by January 2021.
The federal government continues to learn lessons about distributing COVID-19 therapeutics, such as remdesivir, Food and Drug Administration Commissioner Stephen Hahn, M.D., said at a Senate Health, Education, Labor and Pensions Committee hearing.
The National Institutes of Health's National Institute of Allergy and Infectious Diseases released a strategic plan for accelerating research to diagnose, prevent and treat COVID-19.
The Department of Health and Human Services will partner with more than a dozen biopharmaceutical companies and the European Medicines Agency to prioritize vaccine and drug candidates, streamline clinical trials and coordinate regulatory processes to respond to the pandemic, the National Institutes…
The Department of Health and Human Services said it will speed the development and manufacturing of vaccines to prevent COVID-19, starting a candidate from Johnson & Johnson subsidiary Janssen Research & Development.
FDA said it is partnering with the European Medicines Agency (EMA) on regulatory strategies to facilitate the development of COVID-19 vaccines.